RESUMEN
The nucleoside diphosphate (NDP) kinase, Nm23H1, is a highly expressed during neuronal development, whilst induced over-expression in neuronal cells results in increased neurite outgrowth. Extracellular Nm23H1 affects the survival, proliferation and differentiation of non-neuronal cells. Therefore, this study has examined whether extracellular Nm23H1 regulates nerve growth. We have immobilised recombinant Nm23H1 proteins to defined locations of culture plates, which were then seeded with explants of embryonic chick dorsal root ganglia (DRG) or dissociated adult rat DRG neurons. The substratum-bound extracellular Nm23H1 was stimulatory for neurite outgrowth from chick DRG explants in a concentration-dependent manner. On high concentrations of Nm23H1, chick DRG neurite outgrowth was extensive and effectively limited to the location of the Nm23H1, i.e. neuronal growth cones turned away from adjacent collagen-coated substrata. Nm23H1-coated substrata also significantly enhanced rat DRG neuronal cell adhesion and neurite outgrowth in comparison to collagen-coated substrata. These effects were independent of NGF supplementation. Recombinant Nm23H1 (H118F), which does not possess NDP kinase activity, exhibited the same activity as the wild-type protein. Hence, a novel neuro-stimulatory activity for extracellular Nm23H1 has been identified in vitro, which may function in developing neuronal systems.
Asunto(s)
Ganglios Espinales/efectos de los fármacos , Nucleósido Difosfato Quinasas NM23/farmacología , Neuritas/efectos de los fármacos , Neuronas/efectos de los fármacos , Proteínas Recombinantes/farmacología , Animales , Células Cultivadas , Embrión de Pollo , Colágeno Tipo I/farmacología , Ganglios Espinales/crecimiento & desarrollo , Masculino , Nucleósido Difosfato Quinasas NM23/genética , Factor de Crecimiento Nervioso/farmacología , Neuritas/fisiología , Neuronas/fisiología , Ratas , Ratas Sprague-Dawley , Proteínas Recombinantes/genéticaRESUMEN
Thyroid carcinoma cells often do not express thyroid-specific genes including sodium iodide symporter (NIS), thyroperoxidase (TPO), thyroglobulin (TG), and thyrotropin-stimulating hormone receptor (TSHR). Treatment of thyroid carcinoma cells (four papillary and two anaplastic cell lines) with histone deacetylase inhibitors (SAHA or VPA) modestly induced the expression of the NIS gene. The promoter regions of the thyroid-specific genes contained binding sites for hepatocyte nuclear factor 3 beta (HNF3 beta)/forkhead box A2 (FoxA2), thyroid transcription factor 1 (TTF-1), and CCAAT/enhancer binding protein (C/EBP beta). Quantitative reverse transcription-polymerase chain reaction (RT-PCR) showed decreased expression of HNF3 beta/FoxA2 and TTF-1 mRNA in papillary thyroid carcinoma cell lines, when compared with normal thyroid cells. Forced expression of these genes in papillary thyroid carcinoma cells inhibited their growth. Furthermore, the CpG island in the promoter region of HNF3 beta/FoxA2 was aberrantly methylated; and treatment with 5-aza-2-deoxycytidine (5-Az) induced its expression. Immunohistochemical staining showed that C/EBP beta was localised in the nucleus in normal thyroid cells but was detected in the cytoplasm in papillary thyroid carcinoma cells. Subcellular fractionation of papillary thyroid carcinoma cell lines also demonstrated high levels of expression of C/EBP beta in the cytoplasm, suggesting that a large proportion of C/EBP beta protein is inappropriately localised in the cytoplasm. In summary, these findings reveal novel abnormalities in thyroid carcinoma cells.
Asunto(s)
Proteína beta Potenciadora de Unión a CCAAT/fisiología , Regulación Neoplásica de la Expresión Génica/fisiología , Factor Nuclear 3-beta del Hepatocito/fisiología , Proteínas Nucleares/fisiología , Simportadores/genética , Neoplasias de la Tiroides/genética , Factores de Transcripción/fisiología , Secuencia de Bases , Proteína beta Potenciadora de Unión a CCAAT/genética , Línea Celular Tumoral , Metilación de ADN , Cartilla de ADN , Factor Nuclear 3-beta del Hepatocito/genética , Humanos , Inmunohistoquímica , Proteínas Nucleares/genética , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Neoplasias de la Tiroides/patología , Factor Nuclear Tiroideo 1 , Factores de Transcripción/genéticaRESUMEN
Histone deacetylase inhibitors (HDIs) are a new class of drugs with significant antileukemic activity. To explore mechanisms of disease-specific HDI activity in acute myeloid leukaemia (AML), we have characterised expression of all 18 members of the histone deacetylase family in primary AML blasts and in four control cell types, namely CD34+ progenitors from umbilical cord, either quiescent or cycling (post-culture), cycling CD34+ progenitors from GCSF-stimulated adult donors and peripheral blood mononuclear cells. Only SIRT1 was consistently overexpressed (>2 fold) in AML samples compared with all controls, while HDAC6 was overexpressed relative to adult, but not neo-natal cells. HDAC5 and SIRT4 were consistently underexpressed. AML blasts and cell lines, exposed to HDIs in culture, showed both histone hyperacetylation and, unexpectedly, specific hypermethylation of H3 lysine 4. Such treatment also modulated the pattern of HDAC expression, with strong induction of HDAC11 in all myeloid cells tested and with all inhibitors (valproate, butyrate, TSA, SAHA), and lesser, more selective, induction of HDAC9 and SIRT4. The distinct pattern of HDAC expression in AML and its response to HDIs is of relevance to the development of HDI-based therapeutic strategies and may contribute to observed patterns of clinical response and development of drug resistance.
Asunto(s)
Inhibidores Enzimáticos/farmacología , Inhibidores de Histona Desacetilasas , Histona Desacetilasas/metabolismo , Histonas/metabolismo , Leucemia Mieloide/enzimología , Acetilación , Enfermedad Aguda , Adulto , Antígenos CD34/metabolismo , Butiratos/farmacología , Metilación de ADN , Regulación Enzimológica de la Expresión Génica , Regulación Neoplásica de la Expresión Génica , Humanos , Ácidos Hidroxámicos/farmacología , Leucemia Mieloide/tratamiento farmacológico , Leucemia Mieloide/genética , Células Mieloides , Células Tumorales Cultivadas , Ácido Valproico/farmacología , VorinostatRESUMEN
Metabolic transformation in cancer is increasingly well understood. However, little is known about the metabolic responses of cancer cells that permit their survival in different microenvironments. We have used a nuclear magnetic resonance based approach to monitor metabolism in living primary chronic lymphoid leukemia (CLL) cells and to interrogate their real-time metabolic responses to hypoxia. Our studies demonstrate considerable metabolic plasticity in CLL cells. Despite being in oxygenated blood, circulating CLL cells are primed for hypoxia as measured by constitutively low level hypoxia-inducible factor (HIF-1α) activity and modest lactate production from glycolysis. Upon entry to hypoxia we observed rapid upregulation of metabolic rates. CLL cells that had adapted to hypoxia returned to the 'primed' state when re-oxygenated and again showed the same adaptive response upon secondary exposure to hypoxia. We also observed HIF-1α independent differential utilization of pyruvate in oxygenated and hypoxic conditions. When oxygenated, CLL cells released pyruvate, but in hypoxia imported pyruvate to protect against hypoxia-associated oxidative stress. Finally, we identified a marked association of slower resting glucose and glutamine consumption, and lower alanine and lactate production with Binet A0 stage samples indicating that CLL may be divided into tumors with higher and lower metabolic states that reflect disease stage.
Asunto(s)
Adaptación Fisiológica , Leucemia Linfocítica Crónica de Células B/metabolismo , Puntos de Control del Ciclo Celular , Hipoxia de la Célula , Ciclo del Ácido Cítrico , Humanos , Subunidad alfa del Factor 1 Inducible por Hipoxia/análisis , Espectroscopía de Resonancia Magnética , Ácido Pirúvico/farmacologíaRESUMEN
Cathepsin B synthesis by the human HL60 promyelocyte cell line was investigated by immunohistochemistry and by the assay of the enzyme in cell lysates using a fluorimetric substrate. HL60 cells were shown to produce cathepsin B in response to treatment with 12-O-tetradecanoylphorbol 13-acetate (TPA). Intracellular levels of cathepsin B and immunohistochemical staining of the enzyme were related to time in culture with increasing concentrations of TPA from 1 nmol/1 to 8.0 nmol/1. Synthesis of cathepsin B was associated with TPA-induced phagocytic activity of cells in culture, expression of alpha-naphthyl acetate esterase and reduced cell division. Cathepsin B production was, therefore, related to differentiation of the HL60 promyelocytes into mature macrophage-like cells. Cathepsin B activity in HL60 cell lysates was significantly increased by incubation of the cells with 10 micrograms/ml endotoxin (lipopolysaccharide) from Escherichia coli, but not carrageenan. The production of cathepsin B by TPA-induced HL60 cells was significantly reduced by 0.25 mumol/1 dexamethasone and the non-steroidal anti-inflammatory compound 4-(6-methoxy-2-naphthyl)-butan-2-one but not by indomethacin. The HL60 promyelocytic cell line is a useful model for the study of factors affecting proteinase synthesis by human mononuclear phagocytes.
Asunto(s)
Catepsinas/biosíntesis , Macrófagos/enzimología , Monocitos/enzimología , Antiinflamatorios/farmacología , Butanonas/farmacología , Carboxilesterasa , Hidrolasas de Éster Carboxílico/metabolismo , Carragenina/farmacología , Catepsina B , Diferenciación Celular/efectos de los fármacos , Línea Celular , Dexametasona/farmacología , Endotoxinas/farmacología , Humanos , Indometacina/farmacología , Leucemia Mieloide Aguda/enzimología , Nabumetona , Fagocitosis , Acetato de Tetradecanoilforbol/farmacologíaRESUMEN
[3H]Inositol uptake by HL60 cells was measured during DMSO-induced differentiation towards neutrophils. The values for Km (53.2 microM) and Vmax (5.3 pmol/min per 10(6) cells) obtained for control HL60 cells are in good agreement with previously published figures for this cell line. Inositol transport into HL60 cells was an active, saturable and specific process which was unaffected by extracellular glucose concentrations. Inositol transport rates changed during DMSO-induced differentiation of HL60 cells towards neutrophils. An increase in inositol transport rates occurred during the first 4 days of exposure to 0.9% DMSO and was concommitant with the period leading to growth arrest and prior to the acquisition of the differentiated phenotype. These changes preceded the rise in intracellular inositol concentration from 10.9 to 132.7 microM seen between day 1 and day 5. After 4 days exposure to DMSO the rate of inositol transport fell to a value of 3.2 +/- 0.3 pmol/min per 10(6) cells at day 7, this was accompanied by a small reduction in intracellular inositol from a peak value of 132.7 to 112 microM. The inositol transport rate, thus, appears to closely accompany changes in the intracellular concentration of inositol. Inositol transport in human peripheral blood neutrophils was an order of magnitude slower than the value for uninduced HL60 cells, but the Km for inositol transport was similar in both cell types and was unchanged during HL60 differentiation. This suggests that changes in inositol transport rate are achieved by the modulation of a commonly expressed inositol transporter, one consequence of which is the alteration of intracellular inositol concentrations.
Asunto(s)
Dimetilsulfóxido/farmacología , Inositol/metabolismo , Neutrófilos/efectos de los fármacos , Transporte Biológico Activo/efectos de los fármacos , Proteínas Portadoras/metabolismo , Diferenciación Celular/efectos de los fármacos , Glucosa/farmacología , Humanos , Inositol/farmacocinética , Proteínas de Transporte de Monosacáridos/metabolismo , Neutrófilos/metabolismo , Células Tumorales Cultivadas/efectos de los fármacos , Células Tumorales Cultivadas/metabolismoRESUMEN
We have analysed the levels of soluble inositol metabolites in HL60 cells as they differentiate towards neutrophils in response to a combination of all-trans-retinoic acid and granulocyte colony-stimulating factor and towards monocytes in response to 1 alpha-25-dihydroxyvitamin D3. In both cases, differentiation was accompanied by increases in intracellular inositol (Ins), glycerophosphoinositol (GroPIns) and inositol pentakisphosphate (InsP5) concentrations. [GroPIns] reached a peak early in the differentiation of both neutrophils and monocytes and subsequently fell to about double the starting level as the cells acquired mature characteristics, and [InsP5] rose later. Similarly, neutrophils derived in culture by the spontaneous differentiation of myeloid blast cells contained increased levels of Ins, GroPIns and InsP5 when compared to their parental blast cells. We have also compared the inositol metabolites present in two pairs of cell lines which are representative of immature and mature B and T lymphocytes. The mature cells again contained the higher levels of GroPIns and InsP5. We have previously demonstrated increases in Ins, GroPIns and Ins(1,3,4,5,6)P5 levels during the differentiation of HL60 cells towards neutrophils in response to DMSO and of GroPIns during the monocytoid differentiation of normal primitive myeloid blast cells in response to PMA. These observations suggest that deacylation of phosphatidylinositol by a phospholipase A/lysophospholipase pathway, forming GroPIns and probably also regulatory arachidonate metabolites, has some role in haemopoietic cell differentiation. The reasons why Ins(1,3,4,5,6)P5 and Ins accumulate during haemopoietic differentiation remain unknown.
Asunto(s)
Diferenciación Celular , Células Madre Hematopoyéticas/citología , Fosfatos de Inositol/análisis , Inositol/análisis , Fosfatidilinositoles/análisis , Línea Celular , Factor Estimulante de Colonias de Granulocitos/farmacología , Humanos , Monocitos/citología , Neutrófilos/citología , Tretinoina/farmacologíaRESUMEN
HL60 cells are human promyeloid cells that can be induced to differentiate by physiological stimuli (e.g. all-trans retinoic acid (ATRA), 1 alpha,25-dihydroxyvitamin D3 (D3), granulocyte colony-stimulating factor (G-CSF)) and by non-physiological agents such as dimethysulphoxide (DMSO) and protein kinase C-activating phorbol esters. The sensitivity of HL60 cells to physiological differentiating agents, but not to DMSO, is enhanced when cells are exposed to 'anti-inflammatory agents' (e.g. indomethacin) or are 'primed' (pretreated) with a small amount of ATRA: alone, neither treatment induces differentiation. We earlier suggested that indomethacin might act by inhibiting the endogenous formation of a differentiation-suppressing prostanoid (Bunce, C.M., et al. (1994) Leukemia 8, 595-604). Studies of the formation of prostanoids by HL60 cells and of the effects of prostanoids on these cells failed to identify any prostanoid that could be implicated in sensitization by indomethacin. 3 alpha-Hydroxysteroid dehydrogenase (3 alpha-HSD) is another target of such 'anti-inflammatory agents'. Steroid inhibitors of 3 alpha-HSD sensitized HL60 cells to inducers of differentiation in a manner similar to indomethacin. 3 alpha-HSD is a member of the aldoketoreductase enzyme family, which comprises many enzymes of similar size and primary sequence. A protein that was recognised by an antiserum to 3 alpha-HSD was found in HL60 cells, but the cells showed no detectable 3 alpha-HSD activity. The 3 alpha-HSD-like protein was strikingly down-regulated by 'priming' doses of ATRA. When treatment with a differentiation-sensitizing 'anti-inflammatory agent' or steroid was combined with ATRA "priming', the effects of the different treatments were not additive: the resulting increase in sensitivity equalled that achievable by either treatment alone. We conclude that interference with a single intracellular regulatory mechanism underlies the increases in sensitivity of cells to differentiating agents that are caused by anti-inflammatory agents, by certain steroids and by 'priming' with ATRA. Decreased activity of a yet-to-be-identified member of the aldoketoreductase family of dehydrogenases is likely to be a central feature of a previously unrecognised mechanism that controls the responsiveness of cells to environmental stimuli such as retinoids and D3.
Asunto(s)
3-Hidroxiesteroide Deshidrogenasas/metabolismo , Antiinflamatorios no Esteroideos/farmacología , Dexametasona/farmacología , Monocitos/citología , Neutrófilos/citología , Tretinoina/farmacología , Ácido Araquidónico/metabolismo , Aspirina/farmacología , Diferenciación Celular/efectos de los fármacos , Colecalciferol/farmacología , Dihidrotestosterona/farmacología , Regulación hacia Abajo , Estradiol/farmacología , Células HL-60 , Humanos , Indometacina/farmacología , Medroxiprogesterona/farmacología , Monocitos/efectos de los fármacos , Monocitos/enzimología , Naftol AS D Esterasa/metabolismo , Neutrófilos/efectos de los fármacos , Neutrófilos/enzimología , Nitroazul de Tetrazolio/metabolismo , Prostaglandinas/metabolismo , Prostaglandinas/farmacologíaRESUMEN
Diabetes mellitus is associated with a significant reduction in the serum concentration of Mg2+. Several studies have suggested that hypomagnesemia may be implicated in the etiology of diabetic complications; however, no mechanism has been proposed. This study demonstrates that Mg2+ is a positive effector of inositol transport and is capable of promoting a 2.5-fold increase in the affinity of the transporter for inositol. Analysis of the kinetics of inositol transport shows that, at physiological concentrations of inositol, the reductions in Mg2+ concentrations that occur in diabetic patients would result in a significant decline in the rate of inositol transport (1.5- to 2-fold). We suggest that hypomagnesemia may be linked to the development of diabetic complications via reduction in the rate of inositol transport and subsequent intracellular inositol depletion. This assertion allows hypomagnesemia and the polyol theory to be unified into one mechanistic model for the development of diabetic complications.
Asunto(s)
Diabetes Mellitus/fisiopatología , Inositol/metabolismo , Magnesio/farmacología , Magnesio/fisiología , Sodio/farmacología , Transporte Biológico/efectos de los fármacos , Línea Celular , Complicaciones de la Diabetes , Humanos , CinéticaRESUMEN
Analysis of the nonclassic actions of vitamin D(3) has highlighted a wide range of target tissues for the hormone 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)]. Systemic or locally produced 1,25(OH)(2)D(3) may play a role in modulating cell development processes such as hematopoiesis. The mechanisms by which 1,25(OH)(2)D(3) achieves this are discussed in this review. In particular, data from our laboratories suggest that 1,25(OH)(2)D(3) does not provide a deterministic signal for monocyte differentiation. Rather, the hormone acts as a permissive agent for myeloid precursor cells to enter a genetically determined terminal maturation pathway. The effiacy of 1,25(OH)(2)D(3) in leukemia therapy has been improved by the development of novel vitamin D analogues that have potent antiproliferative activity and low hypercalcemic side effects. Another solution to the problem of side effects is to enhance specifically the antiproliferative effects of 1,25(OH)(2)D(3). A novel mechanism within hematopoiesic cells that governs their responsiveness to the antiproliferative/differentiative actions of 1,25(OH)(2)D(3) outlined.
RESUMEN
A basis for differentiation therapy of leukemias is provided by knowledge of agents which induce specific lineage maturation. All-trans retinoic acid (RA) induces differentiation of HL60 cells to neutrophils and is used to treat acute promyelocytic leukemia. We observed that RA did not induced neutrophil differentiation in serum-free grown HL60 cells whereas 50 nM 1 alpha,25-dihydroxyvitamin D3 (D3) induced maximal monocyte differentiation. Increasing RA concentrations reduced the D3 concentration required for monocyte differentiation. Cells treated with 5 nM D3 showed little response, but differentiated maximally with 5 nM D3 and 10 nM RA. The D3 analogs MC903, EB1089 and KH1060 were more potent inducers of monocyte differentiation. The extent to which analog activity was increased after cotreatment with RA was inversely related to potency. Twenty-four hour treatment with 10 nM RA primed cells for response to 5 nM D3; the reverse sequence being ineffective. Priming with 10 nM RA, or subsequent treatment with D3 (5 nM), did not alter expression of mRNAs encoding receptors for D3 (VDR), RA (RAR alpha) or 9-CIS RA (RXR alpha, beta, gamma). That RA promotes both neutrophil and monocyte differentiation has implications for the use of RA and D3 in treatment of leukemias and provides insight into mechanisms whereby RAR, VDR and RXR facilitate monocyte differentiation.
Asunto(s)
Calcitriol/farmacología , Leucemia Promielocítica Aguda/patología , Monocitos/efectos de los fármacos , Tretinoina/farmacología , Calcitriol/análogos & derivados , Diferenciación Celular/efectos de los fármacos , Sinergismo Farmacológico , Humanos , Leucemia Promielocítica Aguda/metabolismo , Monocitos/patología , Neutrófilos/efectos de los fármacos , Neutrófilos/patología , ARN Mensajero/análisis , Receptores de Calcitriol/genética , Receptores de Ácido Retinoico/genética , Células Tumorales Cultivadas/efectos de los fármacos , Células Tumorales Cultivadas/metabolismo , Células Tumorales Cultivadas/patologíaRESUMEN
The promyeloid cell line HL60, when grown in serum-free medium, is induced to differentiate towards either neutrophils or monocytes by treatment with particular concentrations of 9-cis retinoic acid (9-cis RA) and 1 alpha, 25 dihydroxyvitamin D3 (D3). We have investigated whether treatment of HL60 cells with 9-cis RA and D3 can lead to growth arrest and a failure to undergo cell differentiation. This occurred in two circumstances and HL60 cells died rapidly by apoptosis. First, treatment with 5 x 10(-7) M 9-cis RA and 1.25 x 10(-9)-3.1 x 10(-10) M D3 promoted growth arrest and apoptosis of HL60 cells. The amount of 9-cis RA alone promoted significant neutrophil differentiation of HL60 cells. The amounts of D3 alone promoted a very low level of monocyte differentiation. Treatment with each agent alone did not result in increased levels of apoptosis. Second, HL60 cells were treated with concentrations of 9-cis RA (5 x 10(-7) M) and D3 (3.9 x 10(-14) M) that were appropriate for induction of neutrophil differentiation. At the time when they were undergoing commitment to the neutrophil pathway of differentiation (days 1-2), an amount of D3 (1 x 10(-7) M) that promotes monocyte differentiation was added to the cultures. HL60 cells failed to differentiate and died by apoptosis. Hence, certain combinations of signals, elicited by 9-cis RA and D3, promote apoptosis of HL60 cells. This finding has important implications for the use of retinoids and D3 in differentiation therapy.
Asunto(s)
Apoptosis/efectos de los fármacos , Calcitriol/farmacología , Leucemia Promielocítica Aguda/patología , Transducción de Señal , Tretinoina/farmacología , Diferenciación Celular/efectos de los fármacos , Sinergismo Farmacológico , Humanos , Monocitos/efectos de los fármacos , Monocitos/patología , Neutrófilos/efectos de los fármacos , Neutrófilos/patología , Células Tumorales Cultivadas/efectos de los fármacos , Células Tumorales Cultivadas/patologíaRESUMEN
We have confirmed previous observations that HL60 cells treated with a combination of 10 nM retinoic acid (RA), and 30 ng/ml granulocyte colony-stimulating factor (G-CSF) differentiate efficiently towards neutrophils, as characterized by their growth arrest and acquisition of phagocytic ability. Such low concentrations of RA alone provoked only a small proportion of HL60 cells to differentiate, and G-CSF alone provoked no differentiation. In the presence of 30 microM indomethacin (an inhibitor of the enzyme cyclooxygenase that catalyses the first step of prostanoid synthesis), the onset of differentiation provoked by RA plus G-CSF was more rapid, but the final proportion of mature cells was unchanged. Indomethacin also potentiated the growth arrest and differentiation of cells in response to 10 nM RA alone. Although the potentiating effect of indomethacin on RA-induced differentiation occurred at several indomethacin and RA concentrations, it was only apparent when the RA concentration used was alone sufficient to induce a small proportion of cells to differentiate. Indomethacin shifted the G-CSF dose-response curve of cells treated with 10 nM RA to lower G-CSF concentrations. 1 alpha,25-dihydroxy vitamin D3 (VitD3) induces HL60 cells to differentiate to monocytes and indomethacin also potentiated the differentiation of HL60 cells in response to low doses of VitD3 5,8,11-eicosatriynoic acid, an inhibitor of 5-lipoxygenase and 12-lipoxygenase, neither potentiated neutrophil differentiation of HL60 cells, nor prevented indomethacin potentiation of the differentiation of RA-primed cells. Treatment of cells with dexamethasone, a steroid whose effects include inhibition of arachidonate mobilization by phospholipase A2, potentiated RA-primed neutrophil differentiation in a manner similar to indomethacin. These observations suggest that an arachidonate metabolite formed downstream of cyclooxygenase suppresses differentiation of HL60 cells both to neutrophils and monocytes, probably by inhibiting some event essential to commitment to differentiation.
Asunto(s)
Factor Estimulante de Colonias de Granulocitos/farmacología , Indometacina/farmacología , Leucemia Promielocítica Aguda/patología , Neutrófilos/patología , Tretinoina/farmacología , Ácido Araquidónico/metabolismo , Diferenciación Celular/efectos de los fármacos , Colecalciferol/farmacología , Relación Dosis-Respuesta a Droga , Sinergismo Farmacológico , Humanos , Lipooxigenasa/metabolismo , Células Tumorales CultivadasRESUMEN
It is well documented that treatment of serum-grown HL60 cells with 10(-7) M all-trans retinoic acid (all-trans RA) induces neutrophil differentiation, whereas treatment with 10(-7) M 1 alpha,25 dihydroxyvitamin D3(D3) induces differentiation towards monocytes. In recent investigations, using serum-free grown HL60 cells, we observed that all-trans RA, at 10(-7) M, did not induce neutrophil differentiation and that all-trans RA, at 10(-8) M, reduced the D3 concentration required for monocyte differentiation to 5 x 10(-9) M. In this study, co-operative interactions between all-trans and 9-cis RA and D3 which promote neutrophil and monocyte differentiation of HL60 cells have been analysed in detail. Treatment of serum-free grown HL60 cells with 5 x 10(-7) M all-trans RA or 9-cis RA resulted in sub-optimal neutrophil differentiation (up to 25% mature cells). As shown for all-trans RA, 9-cis RA cooperated with D3 to promote monocyte differentiation. Culture of HL60 cells in 5 x 10(-7) M 9-cis RA together with a wide range of concentrations of D3 resulted in promotion of neutrophil differentiation at 10(-15)-10(-12) D3, a failure to differentiate and apoptosis at 10(-11)-10(-10) M D3, followed by co-operativity between 9-cis RA and 5 x 10(-9) M D3 in inducing monocyte differentiation in the absence of neutrophil differentiation. Similar results were obtained when HL60 cells were treated with 5 x 10(-7) all-trans RA together with a wide range of concentrations of D3. Cross titration analyses of the effects of 9-cis RA and D3 on HL60 cell differentiation were undertaken to determine the boundaries of the concentrations of each agent, alone and in combination, that give rise to optimal neutrophil and monocyte differentiation of HL60 cells. The observed cooperativities between either 9-cis RA or all-trans RA and D3 have important implications for the use of combinations of these agents in differentiation therapy.
Asunto(s)
Calcitriol/farmacología , Leucemia Promielocítica Aguda/patología , Monocitos , Células Madre Neoplásicas/efectos de los fármacos , Neutrófilos , Tretinoina/farmacología , Apoptosis/efectos de los fármacos , Diferenciación Celular/efectos de los fármacos , División Celular/efectos de los fármacos , Medio de Cultivo Libre de Suero , Relación Dosis-Respuesta a Droga , Interacciones Farmacológicas , Humanos , Proteínas de Neoplasias/efectos de los fármacos , Proteínas de Neoplasias/fisiología , Células Madre Neoplásicas/patología , Receptores de Calcitriol/efectos de los fármacos , Receptores de Calcitriol/fisiología , Receptores de Ácido Retinoico/efectos de los fármacos , Receptores de Ácido Retinoico/fisiología , Células Tumorales Cultivadas/efectos de los fármacosRESUMEN
Current therapies for Burkitt's lymphoma (BL) utilise combined cytotoxic chemotherapy, but these treatments are not always available in areas where the disease is endemic and are also markedly less successful in AIDS-related BL. Therefore, additional therapies are urgently required. We demonstrate here that combined fibrates and MPA exert powerful, antiproliferative actions against well-characterised Daudi, Raji and L3055 BL cell lines and primary BL cells. Detailed studies in L3055 demonstrated that this activity was mediated by induced apoptosis and confirmed by observations that overexpression of the antiapoptotic genes bcl-2 or bcl-x(L) conferred significant protection against the drugs. Importantly, since fibrates and MPA are inexpensive and stable with minimal-associated toxicities, we suggest that these drugs should be considered as adjuncts to currently available treatments for BL in endemic and AIDS-related disease.
Asunto(s)
Antineoplásicos Hormonales/farmacología , Apoptosis/efectos de los fármacos , Linfoma de Burkitt/patología , Ácido Clofíbrico/farmacología , Hipolipemiantes/farmacología , Acetato de Medroxiprogesterona/farmacología , Linfoma de Burkitt/tratamiento farmacológico , División Celular/efectos de los fármacos , Interacciones Farmacológicas , Quimioterapia Combinada , Humanos , Proteínas Proto-Oncogénicas c-bcl-2/genética , Proteínas Proto-Oncogénicas c-bcl-2/farmacología , Transducción Genética , Células Tumorales Cultivadas , Proteína bcl-XRESUMEN
Primitive myeloid blast cells (2-10 x 10(6)) were purified from 18-22-week fetal liver-derived mononuclear cell preparations by negative selection followed by counterflow cell elutriation. The cells, when maintained in liquid culture in the presence of 100 U/ml interleukin-3 (IL-3) for the first 5 days and 10 U/ml IL-3 and 30 ng/ml granulocyte colony-stimulating factor thereafter, underwent considerable proliferation resulting in an approximately 30-fold increase in cell number by day 14. Analyses of cell morphology and of the numbers of cells that expressed the neutrophil-associated antigen CD15, the monocyte-associated antigen 61D3, and enzymes alpha-naphthyl acetate esterase (ANAE), human leukocyte elastase, and cathepsin G revealed that proliferation of the cells was associated with their concomitant differentiation toward neutrophils and monocytes. The cultures generated predominantly neutrophils; by day 14, wells seeded with 2 x 10(5) cells produced approximately 5 x 10(6) neutrophils as opposed to only approximately 3.5 x 10(5) cells with a monocytoid morphology. This predominance of granulocytopoiesis over monocytopoiesis was confirmed by the numbers of cells that had acquired expression of the CD15 antigen and ANAE, which were approximately 2 x 10(6) and 1 x 10(5), respectively. By contrast, parallel cultures containing 100 nM 1 alpha,25-dihydroxyvitamin D3 (VitD3) generated more monocytes than neutrophils. At day 14, VitD3-treated cultures contained approximately 2 x 10(6) cells with morphologies consistent with their differentiation toward monocytes and approximately 1 x 10(6) ANAE-positive cells, compared with approximately 9.5 x 10(5) cells having morphologies of granulocyte-series cells and approximately 4.5 x 10(4) CD15-positive cells. In both control and VitD3-treated cultures, the enzymes cathepsin G and human leukocyte elastase were expressed almost exclusively by cells that were differentiating toward neutrophils. These data reveal that VitD3 promotes monocytopoiesis and suppresses granulocytopoiesis of primitive blast cells.
Asunto(s)
Calcitriol/farmacología , Granulocitos/citología , Hematopoyesis/efectos de los fármacos , Monocitos/citología , Catepsina G , Catepsinas/fisiología , Ciclo Celular/efectos de los fármacos , Ciclo Celular/fisiología , Diferenciación Celular/efectos de los fármacos , División Celular/efectos de los fármacos , Células Cultivadas , Granulocitos/efectos de los fármacos , Granulocitos/enzimología , Células Madre Hematopoyéticas/citología , Células Madre Hematopoyéticas/efectos de los fármacos , Humanos , Elastasa de Leucocito , Activación de Linfocitos/efectos de los fármacos , Modelos Biológicos , Monocitos/efectos de los fármacos , Monocitos/enzimología , Elastasa Pancreática/fisiología , Fagocitos/efectos de los fármacos , Serina EndopeptidasasRESUMEN
The HL60 line can be induced to differentiate into neutrophils by 1.25% dimethylsulphoxide (DMSO) or monocytes by 12-O-tetradecanoylphorbol-13-acetate (TPA). Seven variants of this line have been isolated which do not respond to 1.25% DMSO. Five of these lines can be induced to mature into neutrophils using DMSO concentrations of 1.75% (HL60 m2, m4, Sp1 and Ast3) and 2.0% (HL60 Ast25). Two lines, HL60 Ast1 and 4, showed minimal differentiation even at a concentration of 2.0% DMSO, and 2.25% DMSO was toxic to these cells. Of the seven variant lines, HL60 Ast3, Ast4 and Sp1 failed to differentiate into monocytes in response to TPA. Sublines from HL60 that either require higher concentrations of DMSO to induce maturation or fail to differentiate into neutrophils, such as those described above, can be used to investigate how genetically determined properties within HL60 cells affect the ability to mature into neutrophils.
Asunto(s)
Dimetilsulfóxido/farmacología , Monocitos/citología , Neutrófilos/citología , Antígenos de Superficie/inmunología , Diferenciación Celular/efectos de los fármacos , Línea Celular , Separación Celular , Resistencia a Medicamentos , Variación Genética , Humanos , Monocitos/efectos de los fármacos , Monocitos/inmunología , Neutrófilos/efectos de los fármacos , Neutrófilos/inmunologíaRESUMEN
Various data in the literature suggest that progenitor cells of monocytes and B cells are closely related. In this study we have investigated this notion by using two-dimensional gel electrophoresis patterns of total cellular phosphoproteins to assess the similarity and thus the close relationships between erythroid, granulocyte, monocyte, and B-lymphocyte cell lines that typify immature cells of these lineages. In previous studies, six proteins had been identified whose constitutive phosphorylation correlated with the capacity of HL60 variant cell lines to differentiate towards either neutrophils (four proteins) or monocytes (two proteins). The presence or absence of five of these phosphoproteins in autoradiographs obtained for the pre-B-cell lines Nalm6 and SMSB showed that the pre-B-cell lines most closely resembled lines able to differentiate towards monocytes (HL6015-12, HL60M2, U937, and ML-1) as opposed to lines restricted to neutrophil (HL60Ast3) or erythroid differentiation (K562). The K562 phosphoprotein pattern resembled that obtained for HL60Ast3. Progressive changes in the constitutive phosphorylation of the five proteins were observed suggesting that cells that have acquired the potential for either neutrophil, monocyte, or B-cell differentiation have initially diversified in a linear progressive manner. This observation supports a model for hemopoiesis that suggests that, during progenitor cell development, differentiation potentials are expressed individually in the above order. Two additional phosphoprotein spots were found to be restricted to the pre-B-cell lines. These phosphoproteins, together with those that change their intensity in autoradiographs of erythroid, myeloid, and B-cell lines, suggest that protein phosphorylation plays an important role during cell diversification.
Asunto(s)
Linfocitos B/citología , Células Madre Hematopoyéticas/citología , Monocitos/citología , Fosfoproteínas/metabolismo , Diferenciación Celular , Electroforesis en Gel Bidimensional , Hematopoyesis , Humanos , Punto Isoeléctrico , Peso Molecular , Neutrófilos/citología , Células Tumorales CultivadasRESUMEN
Hormones such as 1 alpha, 25-dihydroxy vitamin D3 (D3), all-trans retinoic acid, and 9-cis retinoic acid stimulate differentiation of myeloid progenitor cells via their interaction with specific hormone receptors. However, the sensitivity of cells to these agents is not merely governed by the expression of their receptors and the availability of ligand to bind them. Recent studies from our group suggested that the actions of D3 and retinoids on myelopoiesis also are influenced by endogenous mechanisms involving other steroid hormones. In this study we examined the influence of local estrogen metabolism on the differentiation of HL60 cells and normal primitive myeloid progenitor cells. Quantitative thin-layer chromatography (TLC) analyses showed that HL60 and normal cells are able to generate estrone (E1) from estradiol (E2). Neither cell population generated significant amounts of E2 from E1. Reverse transcriptase polymerase chain reaction and Northern analyses confirmed that normal and leukemic myeloid progenitor cells expressed mRNA for the type I and IV isoforms of 17 beta-hydroxysteroid dehydrogenase. Conversion of E2 to E1 was upregulated within 24 hours when HL60 cells were treated with either all-trans retinoic acid or D3 at doses that induce their differentiation toward neutrophils or monocytes, respectively. Similarly, D3-induced monocyte differentiation of normal myeloid progenitor cells was associated with increased capacity to generate E1 from E2. When HL60 cells or normal myeloid progenitor cells were exposed to exogenous E1 they became more sensitive to the differentiation-inducing effects of D3. Data presented provide further evidence for the local modulation of myelopoiesis by intracrine mechanisms. In particular, our findings suggest that local metabolism of steroids by normal as well as leukemic myeloid cells influences their responsiveness to D3 and retinoids.